Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Adverum Biotechnlgs (ADVM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 198,034
  • Shares Outstanding, K 62,868
  • Annual Sales, $ 1,850 K
  • Annual Income, $ -56,150 K
  • 36-Month Beta 3.31
  • Price/Sales 92.47
  • Price/Cash Flow N/A
  • Price/Book 0.92

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.28
  • Number of Estimates 4
  • High Estimate -0.26
  • Low Estimate -0.31
  • Prior Year -0.32
  • Growth Rate Est. (year over year) +12.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.81 +15.30%
on 12/24/18
3.67 -11.72%
on 01/07/19
-0.19 (-5.54%)
since 12/18/18
3-Month
2.62 +23.66%
on 11/02/18
4.72 -31.36%
on 10/19/18
-1.46 (-31.06%)
since 10/18/18
52-Week
2.62 +23.66%
on 11/02/18
8.59 -62.28%
on 01/31/18
-1.41 (-30.32%)
since 01/18/18

Most Recent Stories

More News
Adverum Biotechnologies Provides 2019 Outlook

Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ophthalmology and rare diseases, today reviewed recent progress and provided an outlook...

ADVM : 3.24 (+2.86%)
Adverum to Present at the 37th Annual J.P. Morgan Healthcare Conference

Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ophthalmology and rare diseases, today announced the company will be participating in...

ADVM : 3.24 (+2.86%)
JPM : 104.59 (+1.62%)
What Bargains? Play 5 Stocks With Rising P/E Instead

Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.

ADVM : 3.24 (+2.86%)
RH : 135.32 (+4.39%)
ATHN : 133.83 (+0.18%)
SCON : 1.57 (+3.97%)
SXC : 10.76 (+2.77%)
Adverum Biotechnologies Appoints Mike Fitzgerald as Vice President, Human Resources

Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ophthalmology and rare diseases, today announced the appointment of Mike Fitzgerald...

ADVM : 3.24 (+2.86%)
Adverum Biotechnologies Announces Publication of Preclinical Long-Term Expression and Efficacy Data in Molecular Therapy

Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ophthalmology and rare diseases, today announced the publication of preclinical long-term...

ADVM : 3.24 (+2.86%)
Adverum Announces First Patient Dosed in OPTIC Phase 1 Trial of ADVM-022 Gene Therapy in Wet Age-Related Macular Degeneration

-- ADVM-022 is the first intravitreally delivered gene therapy utilizing directed evolution AAV.7m8 vector for wet AMD

ADVM : 3.24 (+2.86%)
Adverum to Present at 30th Annual Piper Jaffray Healthcare Conference

Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ophthalmology and rare diseases, today announced the company will be participating in...

ADVM : 3.24 (+2.86%)
Adverum Biotechnologies (ADVM) Reports Q3 Loss, Tops Revenue Estimates

Adverum Biotechnologies (ADVM) delivered earnings and revenue surprises of 13.33% and 205.13%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?...

ADVM : 3.24 (+2.86%)
Adverum Biotechnologies: 3Q Earnings Snapshot

MENLO PARK, Calif. (AP) _ Adverum Biotechnologies Inc. (ADVM) on Thursday reported a loss of $21 million in its third quarter.

ADVM : 3.24 (+2.86%)
Adverum Biotechnologies Reports Third Quarter 2018 Financial Results and Provides Corporate Update

Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ophthalmology and rare diseases, today reported financial results for the third quarter...

ADVM : 3.24 (+2.86%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade ADVM with:

Business Summary

Adverum Biotechnologies, Inc. is a gene therapy company. The Company discovers and develops novel medicines for patients living with rare diseases. Adverum Biotechnologies Inc, formerly known as Avalanche Biotechnologies Inc., is headquartered in Menlo Park, California.

See More

Key Turning Points

2nd Resistance Point 3.45
1st Resistance Point 3.35
Last Price 3.24
1st Support Level 3.11
2nd Support Level 2.97

See More

52-Week High 8.59
Fibonacci 61.8% 6.31
Fibonacci 50% 5.61
Fibonacci 38.2% 4.90
Last Price 3.24
52-Week Low 2.62

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar